切换至 "中华医学电子期刊资源库"

中华结直肠疾病电子杂志 ›› 2025, Vol. 14 ›› Issue (03) : 266 -272. doi: 10.3877/cma.j.issn.2095-3224.2025.03.008

液体活检专栏

结直肠癌CTC分选系统的建立及其与组织基因突变的一致性研究
李国雷1,2, 娄莹莹2, 冯浩1, 张维雪1, 贾利辉1, 杨倩2,()   
  1. 1. 050000 石家庄,河北省中医院外一科
    2. 050000 石家庄,河北省浊毒证重点实验室
  • 收稿日期:2025-04-05 出版日期:2025-06-25
  • 通信作者: 杨倩
  • 基金资助:
    河北省医学科学研究课题计划资助(No. 20220077)国家自然科学基金青年科学基金项目(No.82104774)

Establishment of a CTC sorting system for colorectal cancer and study of its consistency with tissue gene mutations

Guolei Li1,2, Yingying Lou2, Hao Feng1, Weixue Zhang1, Lihui Jia1, Qian Yang2,()   

  1. 1. Department of Surgery, Hebei Provincial Hospital of Traditional Chinese Medicine, Shijiazhuang 050000, China
    2. Hebei Provincial Key Laboratory of Turbidoxin Evidence, Shijiazhuang 050000, China
  • Received:2025-04-05 Published:2025-06-25
  • Corresponding author: Qian Yang
引用本文:

李国雷, 娄莹莹, 冯浩, 张维雪, 贾利辉, 杨倩. 结直肠癌CTC分选系统的建立及其与组织基因突变的一致性研究[J/OL]. 中华结直肠疾病电子杂志, 2025, 14(03): 266-272.

Guolei Li, Yingying Lou, Hao Feng, Weixue Zhang, Lihui Jia, Qian Yang. Establishment of a CTC sorting system for colorectal cancer and study of its consistency with tissue gene mutations[J/OL]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2025, 14(03): 266-272.

目的

本研究旨在建立一种高效的结直肠癌循环肿瘤细胞(CTC)分选系统,并探讨CTC代替肿瘤组织进行基因突变检测的可行性。

方法

建立EpCAM与Vimentin抗体修饰的CTC分选系统。通过细胞实验检测CTC分选系统对结直肠癌细胞的分选效率,并对30例结直肠癌患者的CTC进行捕获计数。利用NGS检测患者肿瘤组织样本中热点突变基因,并通过Sanger测序检测血液CTC中热点突变基因,分析肿瘤组织与血液CTC热点基因突变的一致性。

结果

本研究构建的CTC分选系统具有较好的分散性、稳定性及较低的细胞毒性,特异度为90.54%,敏感度为89.07%。结直肠癌患者血液中CTC平均数为(10.90±5.11)个/7.5 mL。通过CTC检出的高频突变基因(TP53、KRAS、EGFR、BRAF、APC、PIK3CA)与组织检测均具有较高的一致性,所有基因总体突变的一致率为(92.89±4.89)%。

结论

基于Ep-LMB/Vi-LMB依次富集的CTC分选系统能够对结直肠癌患者外周血中CTC进行高效捕获。将捕获的CTC用于临床上的热点基因突变检测,在一定程度上解决了肿瘤组织取材困难的问题,具有重要的临床意义。

Objective

The aim of this study was to establish an efficient circulating tumor cells(CTC) sorting system for colorectal cancer and to investigate the feasibility of CTC instead of tumor tissue for gene mutation detection.

Methods

The CTC sorting system modified by EpCAM and Vimentin antibody was established. The sorting efficiency of the CTC sorting system on colorectal cancer cells was detected by cellular experiments, and CTC from 30 colorectal cancer patients were captured and counted. The hotspot mutated genes in patient tumor tissue samples were detected by NGS, and the hotspot mutated genes in blood CTC were detected by Sanger sequencing, and the consistency of hotspot gene mutations between tumor tissues and blood CTC was analyzed.

Results

The CTC sorting system constructed in this study had good dispersion, stability and low cytotoxicity, with a specificity of 90.54% and a sensitivity of 89.07%.The mean number of CTC in the blood of colorectal cancer patients was (10.90±5.11)/7.5 mL. The highfrequency mutated genes (TP53, KRAS, EGFR, BRAF, APC, PIK3CA) detected by CTC were all in high concordance with the tissue assay, and the overall mutation concordance rate for all the genes was (92.89±4.89)%.

Conclusions

The CTC sorting system based on sequential enrichment of Ep-LMB/Vi-LMB is capable of efficiently capturing CTC from peripheral blood of colorectal cancer patients. Using the captured CTC for hotspot mutation detection in the clinic solves the problem of difficult tumor tissue sampling to a certain extent, which is of great clinical significance.

图1 检测流程图(作者李国雷绘制)
图2 LMB的粒径和电位测试。2A:Ep-LMB粒径分布;2B:Vi-LMB粒径分布;2C:Ep-LMB电位分布;2D:Vi-LMB电位分布
图3 细胞捕获效率研究。3A:在PBS中不同捕获方案对CT26细胞的捕获效率;3B:血液模拟系统中不同捕获方案对CT26细胞的捕获效率;3C:在PBS体系中验证捕获系统特异度;3D:在模拟血液系统中验证捕获系统敏感度
图4 临床样本的CTC检测。4A:CTC数量分布散点图;4B:CTC平均数量统计
图5 组织及CTC基因突变检测结果。5A:结直肠癌患者肿瘤组织NGS检测热点基因突变结果;5B:结直肠癌患者血液CTC Sanger法测序检测结果;5C:组织NGS检测与CTC的Sanger法测序基因突变的一致率
[1]
Patel SG, Karlitz JJ, Yen T, et al. The rising tide of early-onset colorectal cancer: a comprehensive review of epidemiology, clinical features, biology, risk factors, prevention, and early detection[J].Lancet Gastroenterol Hepatol, 2022, 7(3): 262-274.
[2]
Shin AE, Giancotti FG, Rustgi AK. Metastatic colorectal cancer:mechanisms and emerging therapeutics[J]. Trends Pharmacol Sci,2023, 44(4): 222-236.
[3]
Cañellas-Socias A, Sancho E, Batlle E. Mechanisms of metastatic colorectal cancer[J]. Nat Rev Gastroenterol Hepatol, 2024, 21(9): 609-625.
[4]
Gu X, Wei S, Lv X. Circulating tumor cells: from new biological insights to clinical practice[J]. Signal Transduct Target Ther, 2024,9(1): 226.
[5]
中华医学会检验医学分会分子诊断学组. 循环肿瘤细胞临床应用与实验室检测专家共识[J]. 中华检验医学杂志, 2021, 44(11): 1008-1020.Molecular Diagnostic Group of Chinese Society of Laboratory Medicine. Chinese expert consensus on clinical application and laboratory test of circulating tumor cells[J]. Chinese Journal of Laboratory Medicine, 2021, 44(11): 1008-1020.
[6]
李国雷, 王赟, 谭国梁, 等. EGFR/Vimentin/Folic Acid磁球检测肺癌循环肿瘤细胞初探[J]. 中国肺癌杂志, 2020, 23(5): 351-359.Li GL, Wang Y, Tan GL, et al. Preliminary study on detection of circulating tumor cells in lung cancer by EGFR/vimentin/folic acid magnetic sphere[J]. Chin J Lung Cancer, 2020, 23(5): 351-359.
[7]
谭国梁, 王赟, 李国雷, 等. 肺癌循环肿瘤细胞EGFR基因突变磁分选技术检测方法及应用研究[J]. 中华肿瘤防治杂志, 2019,26(20): 1515-1524.Tan GL, Wang Y, Li GL, et al. Application of lipid magnetic balls to detection of gene mutations in circulating tumor cells of lung cancer[J].Chin J Cancer Prev Treat, 2019, 26(20): 1515-1524.
[8]
Li G, Hu X, Wang G, et al. Methylation detection of circulating tumor cell miR-486-5p/miR-34c-5p in the progression of colorectal cancer[J].Clin Transl Oncol, 2023, 25(3): 673-684.
[9]
Zhou H, Zhu L, Song J, et al. Liquid biopsy at the frontier of detection,prognosis and progression monitoring in colorectal cancer[J]. Mol Cancer, 2022, 21(1): 86.
[10]
Raza A, Khan AQ, Inchakalody VP, et al. Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer[J]. J Exp Clin Cancer Res, 2022, 41(1): 99.
[11]
Patelli G, Vaghi C, Tosi F, et al. Liquid biopsy for prognosis and treatment in metastatic colorectal cancer: circulating tumor cells vs circulating tumor DNA[J]. Target Oncol, 2021, 16(3): 309-324.
[12]
Yin W, Han YM, Li ZL, et al. Clinical significance of perioperative EMT-CTC in rectal cancer patients receiving open/laparoscopic surgery[J]. Neoplasma, 2020, 67(5): 1131-1138.
[13]
Liu F, Wang S, Lu Z, et al. A simple pyramid-shaped microchamber towards highly efficient isolation of circulating tumor cells from breast cancer patients[J]. Biomed Microdevices, 2018, 20(4): 83.
[14]
Yu Y, Chen Z, Dong J, et al. Folate receptor-positive circulating tumor cells as a novel diagnostic biomarker in non-small cell lung cancer[J].Transl Oncol, 2013, 6(6): 697-702.
[15]
Qi F, Liu Y, Zhao R, et al. Quantitation of rare circulating tumor cells by folate receptor α ligand-targeted PCR in bladder transitional cell carcinoma and its potential diagnostic significance[J]. Tumour Biol,2014, 35(7): 7217-7223.
[16]
Chalfin HJ, Kates M, Toom EEVD, et al. Characterization of urothelial cancer circulating tumor cells with a novel selection-free method[J].Urology, 2018, 115(9): 82-86.
[17]
De Roock W, De Vriendt V, Normanno N, et al. KRAS, BRAF,PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer[J]. Lancet Oncol, 2011, 12(6): 594-603.
[18]
Voutsadakis IA. Sensitivities and dependencies of BRAF mutant colorectal cancer cell lines with or without PIK3CA mutations for discovery of vulnerabilities with therapeutic potential[J]. Medicina(Kaunas), 2022, 58(10): 1498.
[19]
Hofmann MH, Gerlach D, Misale S, et al. Expanding the reach of precision oncology by drugging all KRAS mutants[J]. Cancer Discov,2022, 12(4): 924-937.
[20]
Li W, Qiu T, Guo L, et al. NGS-based oncogenic mutations analysis in advanced colorectal cancer patients improves targeted therapy prediction[J]. Pathol Res Pract, 2019, 215(3): 483-489.
[1] 刘缤妍, 朱昱冰, 李慧敏, 郝梦迪, 刘晓丽, 袁大晋, 黄汶彬, 李文杰, 曾嘉, 丁磊. 术前CT血管造影三维重建在结直肠癌手术中的应用价值:一项荟萃分析[J/OL]. 中华普通外科学文献(电子版), 2025, 19(03): 209-216.
[2] 安霞, 石玉生, 宋智心. 结直肠癌早期筛查的实验室检测策略及临床价值分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(04): 446-448.
[3] 曾舒昊, 康博禹, 郑高赞, 郑建勇, 丰帆. 青年结直肠癌患者的临床病理特征及预后分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(04): 449-452.
[4] 赵晨皓, 张序东, 杨浚沫, 周何. 血清肿瘤标志物对结直肠癌患者术后复发的预测效能研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(04): 467-470.
[5] 杨梦媛, 白启轩, 赵晓琳, 黄坤, 李珍, 曹世长, 程建平. ESD治疗腔内突出型结直肠肿瘤与大肠侧向发育型肿瘤的临床效果对比研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(04): 405-408.
[6] 王珂, 岳育民, 武珍珍, 许泽宇, 惠晓辉, 赵云, 窦维佳, 赵青川. 腹腔镜经自然腔道手术对结直肠癌患者肠道功能及远期效果的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(04): 413-416.
[7] 杜升兰, 张刘平, 肖燕玲. 三种手术策略在结直肠癌并肠梗阻中的临床观察[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(03): 294-297.
[8] 黄展森, 徐锦斌, 黄群雄, 李腾成, 狄金明. 广东省医学会泌尿外科疑难病例多学科会诊(第22期)——ACTH非依赖性双侧肾上腺增生[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(03): 384-389.
[9] 郑秉礼, 彭洁, 孟塬. KRAS基因突变对可切除胰腺癌临床预后的影响[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(03): 456-462.
[10] 姚焕章, 宋华传, 王永帅, 张珅瑜, 王继洲. 同期手术治疗同时性结直肠癌肝转移的安全性与疗效[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 238-244.
[11] 中国医师协会结直肠肿瘤专业委员会. 结直肠癌腹膜转移诊治专家共识(2025版)[J/OL]. 中华结直肠疾病电子杂志, 2025, 14(03): 193-201.
[12] 中国NNOSES联盟, 中国医师协会结直肠肿瘤专业委员会NOSES学组, 中国医师协会结直肠肿瘤专业委员会机器人手术学组, 中国抗癌协会NOSES专业委员会. “机器人”结直肠肿瘤经自然腔道取标本手术专家共识(2025版)[J/OL]. 中华结直肠疾病电子杂志, 2025, 14(03): 202-220.
[13] 周艳, 周泽阳, 程欣萌, 何月娥, 李祥勇, 吴勇. 结直肠癌患者早期造口并发症预测模型的构建与验证[J/OL]. 中华结直肠疾病电子杂志, 2025, 14(03): 242-250.
[14] 沈汶娟, 潘怡, 董林, 邹霜梅. 中国微卫星不稳定大肠癌患者临床病理特征分析[J/OL]. 中华结直肠疾病电子杂志, 2025, 14(03): 251-258.
[15] 陈劲强, 张军明, 黄勇山, 段金元. 腹部无辅助切口经横结肠拖出标本的腹腔镜右半结肠癌根治术一例(附视频)[J/OL]. 中华结直肠疾病电子杂志, 2025, 14(03): 284-288.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?